The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Hosted on MSN1d
Pfizer CEO: Cautiously optimistic on RFK, Jr. HHS secretary nomination
Pfizer CEO Albert Bourla unpacks the impact of the nomination on 'The Claman Countdown.' ...